Diagnostic Precision

A SeraCare blog focused on precision medicine and advanced clinical diagnostics

Choose your Article Focus | NGS | Molecular & Serology

Developing a Rock-Solid Lung Cancer Assay, Part 2

Category: cancer, NGS, Assay Development, Lung Cancer

Posted by Yves Konigshofer, PhD on Jul 2, 2018
In a recent post, we discussed key considerations for designing a robust next-generation sequencing (NGS)-based lung cancer assay. Putting those plans into action in the development phase brings forth a new set of challenges. Through our experience developing NGS reference materials and the relationships we’ve built with assay developers of all stripes, we’ve identified those important factors and ways to navigate them. But before you begin designing and optimizing your assay, you should become very familiar with binomial and Poisson distributions and their use because the outcome of many analytical steps can be modeled and explained with them.
Read More

How am I going to test my assay? Should I use patient samples or biosynthetic materials?

Category: NGS, Assay Development

Posted by Dan Brudzewsky on Jan 4, 2018
Assay development and optimization for clinical genetics is increasingly challenging. In an era of clinical genomics, new technologies and clinical utilities constantly call for newer and better performing assays. Having access to an abundant supply of relevant and reliable test material is critical for quick assay development and well-documented assay performance.
Read More

Accelerating Liquid Biopsy Assay Development

Category: ctDNA, liquid biopsy, Assay Development, reference materials

Posted by Sam Blier on Sep 8, 2017
At the 2017 Next Generation Dx Summit in Washington, DC, our CSO, Russell Garlick, PhD, presented a workshop on accelerating liquid biopsy assay development. He has worked closely with a variety of groups in the liquid biopsy space that are developing and validating circulating tumor DNA (ctDNA) assays. He highlighted some common challenges facing the field, and explained how SeraCare has been using these collaborations to develop QC tools specifically for ensuring the robustness of these cutting-edge tests.
Read More

How Many Target Copies Are Present in Your Plasma DNA Sample?

Category: cancer, ctDNA, liquid biopsy, Assay Development

Posted by Dale Yuzuki on Jun 15, 2017
The field of circulating tumor DNA analysis (ctDNA, also sometimes called in a larger context “liquid biopsy”) holds great promise for monitoring response to cancer treatment, assisting therapeutic choice, monitoring recurrence, and for pre-cancer screening. As such there is a great amount of assay development and ongoing clinical trials; at ClinicalTrials.gov searching for the term "Circulating DNA" you can find over 180 open clinical trials for a wide range of tumor types and interventions.
Read More